EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

Antoine Lebeaud, Leony Antoun, Jane-Rose Paccard, Julien Edeline iD, Hélène Bourien iD, Nadim Fares, Christophe Tournigand, Thierry Lecomte, David Tougeron, Vincent Hautefeuille, Angélique Viénot, Julie Henriques und 11 weitere

Liver International · 2024

DOI: 10.1111/liv.15922 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2024. Verfasst von Antoine Lebeaud und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Biliary Tract Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GERCOR Group, ARCAD (Aide et Recherche en Cancerologie Digestive) Foundation, ACABi (Association pour l'étude des Cancers et Affections des voies Biliaires).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Accumulating data has shown the rising incidence and poor prognosis of early‐onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico‐pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age ≤50 years at diagnosis), versus olders.

Methods

We analysed patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma between 1 January 2003 and 30 June 2021. Baseline characteristics and treatment were described in each group and compared. Progression‐free survival, overall survival and disease‐free survival were estimated in each group using the Kaplan‐Meier method.

Results

Overall, 1256 patients were included, 188 (15%) with EOBTC. Patients with EOBTC demonstrated fewer comorbidities (63.5% vs. 84.5%, p < .0001), higher tumour stage (cT3–4: 50.0% vs. 32.3%, p = .0162), bilobar liver involvement (47.8% vs. 32.1%, p = .0002), and metastatic disease (67.6% vs. 57.5%, p = .0097) compared to older. Patients with EOBTC received second‐line therapy more frequently (89.5% vs. 81.0% non‐EOBTC, p = .0224). For unresectable patients with BTC, median overall survival was 17.0 vs. 16.2 months ( p = .0876), and median progression‐free survival was 5.8 vs. 6.0 months ( p = .8293), in EOBTC vs. older. In advanced stages, fewer actionable alterations were found in EOBTC (e.g., IDH1 mutations [7.8% vs. 16.6%]; FGFR2 ‐fusion [11.7% vs. 8.9%]; p = .029).

Conclusions

Patients with EOBTC have a more advanced disease at diagnosis, are treated more heavily at an advanced stage but show similar survival. A distinctive molecular profile enriched for FGRF2 fusions was found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBiliary Tract NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAgedGallbladder NeoplasmsAge of OnsetAdenocarcinomaBile Duct NeoplasmsPrognosisKaplan-Meier EstimateProgression-Free Survival

Stichwörter der Autor:innen

biliary tract cancerschemotherapycholangiocarcinomaearly onsetmolecular testing

Autor:innen und Institutionen

  • Department of Medical Oncology, CHU Lille, Lille, France.
  • Gustave Roussy Cancer Campus, Villejuif, France.
  • Department of Medical Oncology and Hepatogastroenterology, Lyon University Hospital Center, Hospices Civiles de Lyon, Lyon, France.
  • Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Department of Digestive Oncology, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France.
  • Department of Medical Oncology, Centre Hospitalier Universitaire Henri-Mondor, AP-HP, Creteil, France.

ORCID-Profile: Julien Edeline, Hélène Bourien, Florian Castet, Anthony Turpin

Förderung

  • GERCOR Group
  • ARCAD (Aide et Recherche en Cancerologie Digestive) Foundation
  • ACABi (Association pour l'étude des Cancers et Affections des voies Biliaires)

Zitieren

APA

Lebeaud, A., Antoun, L., Paccard, J. R., Edeline, J., Bourien, H., Fares, N., Tournigand, C., Lecomte, T., Tougeron, D., Hautefeuille, V., Viénot, A., Henriques, J., Williet, N., Bachet, J. B., Smolenschi, C., Hollebecque, A., Macarulla, T., Castet, F., Malka, D., …, & Turpin, A. (2024). Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort. Liver International. https://doi.org/10.1111/liv.15922

Vancouver

Lebeaud A, Antoun L, Paccard JR, Edeline J, Bourien H, Fares N, et al. Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort. Liver International. 2024. doi:10.1111/liv.15922

BibTeX
@article{Lebeaud2024,
  author = {Lebeaud, Antoine and Antoun, Leony and Paccard, Jane-Rose and Edeline, Julien and Bourien, Hélène and Fares, Nadim and Tournigand, Christophe and Lecomte, Thierry and Tougeron, David and Hautefeuille, Vincent and Viénot, Angélique and Henriques, Julie and Williet, Nicolas and Bachet, Jean-Baptiste and Smolenschi, Cristina and Hollebecque, Antoine and Macarulla, Teresa and Castet, Florian and Malka, David and Neuzillet, Cindy and Vernerey, Dewi and Boilève, Alice and Turpin, Anthony},
  title = {Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15922}
}
Kostenlos starten →